IGF-1 LR3 1mg/vial 1 Vial by Bio-Peptide

Usage

1. Reconstitution: inject 1–2 mL of bacteriostatic water slowly along the inner vial wall; swirl gently—never vortex—to dissolve the lyophilised powder completely.
2. Dose calculation: with 1 mL of bacteriostatic water added to 1 mg (1000 mcg), each 0.1 mL drawn in an insulin syringe equals 100 mcg; adjust draw volume to your target dose.
3. Injection timing: administer immediately post-resistance training (within 15–30 minutes) to capitalise on peak GLUT-4 translocation in exercised muscle.
4. Injection site: for hyperplasia-specific protocols, inject intramuscularly into the trained muscle group; subcutaneous injection may be used for systemic nutrient-partitioning effects.
5. Blood glucose monitoring: check capillary glucose 30–60 minutes post-injection, particularly when combining IGF-1 LR3 with high-carbohydrate meals or insulin protocols, to detect excessive glucose disposal.
6. Storage: refrigerate the reconstituted vial at 2–8 °C, protect from light, and discard any unused solution after 30 days to ensure peptide integrity.

Warnings

Frequently asked questions

What makes IGF-1 LR3 more effective than naturally secreted IGF-1 for promoting muscle hyperplasia?

IGF-1 LR3 carries an arginine-3 substitution and an extended N-terminus that prevent it from binding to IGF binding proteins (IGFBPs), which normally sequester endogenous IGF-1 within minutes. The result is a plasma half-life of 20–30 hours versus fewer than 20 minutes for native IGF-1, allowing prolonged IGF-1 receptor activation in satellite cells and a measurably greater stimulus for myofiber proliferation—the biological basis of hyperplasia.

What exactly is muscle cell hyperplasia and why does it matter for long-term physique development?

Muscle hyperplasia is the actual increase in the number of muscle fibers, as opposed to hypertrophy, which is simply the enlargement of existing fibers. Because hyperplasia produces new myofibers—driven by satellite cell activation via the PI3K/Akt pathway—the structural gains are considered permanent architectural changes. This theoretically creates a higher ceiling for future hypertrophic growth, making hyperplasia a qualitatively distinct and longer-lasting adaptation than volumisation alone.

How does IGF-1 LR3 redirect nutrients toward lean muscle rather than fat storage?

IGF-1 LR3 upregulates GLUT-4 transporter expression in skeletal muscle, increasing insulin-independent glucose uptake into myocytes. Research using GLUT-4 protein-density assays in exercised rodent muscle has reported increases of up to 40 % with sustained IGF-1 receptor stimulation. This means dietary carbohydrates are preferentially shuttled into muscle tissue rather than adipose cells—a nutrient-partitioning effect that supports lean-mass gain even in a modest caloric surplus.

How should IGF-1 LR3 1mg vials be reconstituted and stored after opening?

Add 1–2 mL of bacteriostatic water slowly along the vial wall to dissolve the lyophilised powder without agitation. Once reconstituted, store the vial refrigerated at 2–8 °C, away from direct light, and use within 30 days. Never freeze the reconstituted solution, as ice-crystal formation degrades peptide integrity. Draw doses with an insulin syringe (29–31 gauge) to minimise peptide loss in dead space.

When is the optimal time to inject IGF-1 LR3 to maximise its nutrient-partitioning effect?

Immediately post-training is the window most supported by IGF-1 receptor signalling literature: exercised muscle membranes show peak GLUT-4 translocation in response to IGF-1 receptor activation, maximising glucose uptake into myocytes rather than adipocytes. Injecting within 15–30 minutes of finishing resistance training leverages this synergistic GLUT-4 upregulation, directing the caloric substrate available from a post-workout meal toward lean-tissue accrual. (2) angle_used

Manufacturer

Bio-Peptide's reputation among European research-peptide suppliers was built around a founding decision that many competitors treated as commercially impractical: requiring independent, third-party laboratory verification of every batch before any vial could reach a customer. That decision translated into a fixed two-checkpoint release protocol—HPLC (High-Performance Liquid Chromatography) analysis to confirm molecular sequence identity and purity percentage, and a LAL (Limulus Amebocyte Lysate) endotoxin screen to certify injection-grade microbiological safety—both conducted externally and both tied to unique batch identifiers that accompany each product. Over successive production cycles, this model evolved from a founding constraint into a fully systematised quality infrastructure: batch-specific certificates of analysis became standard deliverables rather than on-request documents, giving researchers a verifiable audit trail for every compound they handle. The IGF-1 LR3 1 mg vial reflects that infrastructure directly—each unit ships with documentation confirming it cleared both external verification gates before leaving the facility.